MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $1.10 billion. The enterprise value is $978.01 million.
| Market Cap | 1.10B |
| Enterprise Value | 978.01M |
Important Dates
The last earnings date was Wednesday, October 29, 2025, after market close.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 148.10 million shares outstanding. The number of shares has decreased by -12.06% in one year.
| Current Share Class | 148.10M |
| Shares Outstanding | 148.10M |
| Shares Change (YoY) | -12.06% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 1.76% |
| Owned by Institutions (%) | 45.46% |
| Float | 108.92M |
Valuation Ratios
The trailing PE ratio is 27.55 and the forward PE ratio is 21.97.
| PE Ratio | 27.55 |
| Forward PE | 21.97 |
| PS Ratio | 2.79 |
| Forward PS | 2.63 |
| PB Ratio | 4.61 |
| P/TBV Ratio | 5.29 |
| P/FCF Ratio | 16.49 |
| P/OCF Ratio | 16.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.25, with an EV/FCF ratio of 14.64.
| EV / Earnings | 23.96 |
| EV / Sales | 2.49 |
| EV / EBITDA | 14.25 |
| EV / EBIT | 18.13 |
| EV / FCF | 14.64 |
Financial Position
The company has a current ratio of 4.41, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.41 |
| Quick Ratio | 3.82 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.26 |
| Debt / FCF | 0.27 |
| Interest Coverage | 28.41 |
Financial Efficiency
Return on equity (ROE) is 19.44% and return on invested capital (ROIC) is 14.75%.
| Return on Equity (ROE) | 19.44% |
| Return on Assets (ROA) | 11.98% |
| Return on Invested Capital (ROIC) | 14.75% |
| Return on Capital Employed (ROCE) | 20.65% |
| Revenue Per Employee | $470,062 |
| Profits Per Employee | $48,775 |
| Employee Count | 837 |
| Asset Turnover | 1.40 |
| Inventory Turnover | 2.79 |
Taxes
In the past 12 months, MiMedx Group has paid $14.89 million in taxes.
| Income Tax | 14.89M |
| Effective Tax Rate | 26.73% |
Stock Price Statistics
The stock price has decreased by -0.80% in the last 52 weeks. The beta is 1.63, so MiMedx Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | -0.80% |
| 50-Day Moving Average | 7.03 |
| 200-Day Moving Average | 7.15 |
| Relative Strength Index (RSI) | 56.48 |
| Average Volume (20 Days) | 1,052,988 |
Short Selling Information
The latest short interest is 4.80 million, so 3.24% of the outstanding shares have been sold short.
| Short Interest | 4.80M |
| Short Previous Month | 4.72M |
| Short % of Shares Out | 3.24% |
| Short % of Float | 4.41% |
| Short Ratio (days to cover) | 6.94 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $393.44 million and earned $40.83 million in profits. Earnings per share was $0.27.
| Revenue | 393.44M |
| Gross Profit | 322.58M |
| Operating Income | 53.96M |
| Pretax Income | 55.72M |
| Net Income | 40.83M |
| EBITDA | 68.61M |
| EBIT | 53.96M |
| Earnings Per Share (EPS) | $0.27 |
Balance Sheet
The company has $142.08 million in cash and $18.21 million in debt, giving a net cash position of $123.87 million or $0.84 per share.
| Cash & Cash Equivalents | 142.08M |
| Total Debt | 18.21M |
| Net Cash | 123.87M |
| Net Cash Per Share | $0.84 |
| Equity (Book Value) | 238.95M |
| Book Value Per Share | 1.61 |
| Working Capital | 196.41M |
Cash Flow
In the last 12 months, operating cash flow was $67.83 million and capital expenditures -$1.01 million, giving a free cash flow of $66.82 million.
| Operating Cash Flow | 67.83M |
| Capital Expenditures | -1.01M |
| Free Cash Flow | 66.82M |
| FCF Per Share | $0.45 |
Margins
Gross margin is 81.99%, with operating and profit margins of 13.71% and 10.38%.
| Gross Margin | 81.99% |
| Operating Margin | 13.71% |
| Pretax Margin | 14.16% |
| Profit Margin | 10.38% |
| EBITDA Margin | 17.44% |
| EBIT Margin | 13.71% |
| FCF Margin | 16.98% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 12.06% |
| Shareholder Yield | 12.06% |
| Earnings Yield | 3.71% |
| FCF Yield | 6.06% |
Analyst Forecast
The average price target for MiMedx Group is $12.00, which is 61.29% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.00 |
| Price Target Difference | 61.29% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MiMedx Group has an Altman Z-Score of 10.48 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.48 |
| Piotroski F-Score | 6 |